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ABSTRACT
Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been 
based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or 
edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that 
all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism 
and showed lower rates of intracranial bleeding than those associated with warfarin. However, 
the trials were designed differently, varied in the inclusion/exclusion criteria, and used either 
one dose or a low/high dose of the NOAC drug. Some of these differences have challenged 
the ability to directly compare various NOACs, and comparative data on effectiveness and 
intracranial bleeding are sparse in “real-world” patients. Real-world data complement data 
from large randomized phase III trials by providing new aspects of the “real-world” absolute 
risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, 
“real-world” fragile patients might have been included (e.g., patients with increased risk of 
bleeding, liver disease, and chronic kidney disease), although these patients would be less 
represented in trials. This paper introduces recently published real-world data of NOACs and 
further suggests the recommended dosage of NOACs for Korean patients.
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INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 
1–2% of the general population, and its occurrence has increased rapidly in Korea.1)2) It is 
associated with a 5-fold increase in stroke risk, and one in 5 cases of stroke is attributed to 
this arrhythmia.3) Oral anticoagulant (OAC) treatment can prevent the majority of ischemic 
strokes in patients with AF and prolong life.4) It is superior to no treatment or aspirin in 
patients with different profiles for stroke risk.5) Non-vitamin K antagonist oral anticoagulants 
(NOACs) can have a considerable effect on standard stroke prevention and management in 
AF. Their predictable pharmacodynamics and kinetics as well as fewer drug-drug and drug-
food interactions than those of warfarin can simplify their use by healthcare professionals 
and patients. Several major trials have shown that NOACs have on-par or better efficacy and 
safety than warfarin.6-9)
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Regulatory approvals of NOACs were based on 4 large randomized phase III trials evaluating 
dabigatran (Pradaxa®; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA), 
rivaroxaban (Xarelto®; Janssen Pharmaceuticals, Inc., Titusville, NJ, USA), apixaban (Eliquis®; 
Bristol-Myers Squibb Company, Princeton, NJ, USA), or edoxaban (Savaysa®; Daiichi Sankyo, 
Inc., Parsippany, NJ, USA) vs. warfarin (Coumadin®; Bristol-Myers Squibb Company) for 
AF.6-9) The results of the trials showed that all NOACs were at least non-inferior to warfarin in 
prevention of stroke/thromboembolism (TE). Intracranial bleeding was a safety outcome in 
the trials, and all NOACs were associated with lower rates of intracranial bleeding than was 
warfarin. However, the trials were designed differently, with variations in the inclusion/exclusion 
criteria and either one dose or a low/high dose of the NOAC drug. Some of these differences 
have challenged the ability to directly compare stroke/TE prophylaxis and risk of intracranial 
bleeding with dabigatran, rivaroxaban, or apixaban relative to warfarin. Importantly, results 
of randomized controlled trials are wholly convincing, but comparative data on effectiveness 
and intracranial bleeding are sparse in real-world patients. Recently, a considerable amount of 
real-world data on NOACs has been published (Table 1). Real-world data are complementary to 
those obtained from large randomized phase III trials, providing new information on the “real-
world” absolute risks of ischemic and hemorrhagic stroke with NOACs vs. vitamin K antagonists 
(VKAs). Moreover, real-world fragile patients might have been included (e.g., patients with 
increased risk of bleeding, liver disease, and chronic kidney disease), although these patients 
would be less represented in the trials.10) This paper highlights recently published real-world 
data of NOACs and further recommends NOAC dosages for Korean patients.
REAL-WORLD NOAC DATA: STROKE AND TE
In cohorts of patients with non-valvular AF drawn from a large US database of commercial 
and Medicare supplement claims, dabigatran, rivaroxaban, and apixaban appeared to have 
similar effectiveness.11) In Danish nationwide registries, all NOACs appeared to be safe and 
effective alternatives to warfarin in a routine care setting.12) Recently, Staerk et al.13) reported 
that, in anticoagulant-naïve patients with AF, treatment with dabigatran, rivaroxaban, and 
834https://e-kcj.org https://doi.org/10.4070/kcj.2017.0158
NOAC Real-world Data and Doses for Koreans
Table 1. Comparison of NOACs
Author Study design Region Enrollment period Cohort size Endpoints NOACs analyzed
Laliberté et al.30) RC US May 2011 to Jul 2012 30,479 Effectiveness and bleeding R vs. D
Bouillon et al.31) RC France Jan 2011 to Nov 2012 17,410 Effectiveness and bleeding D, R, or W
Abraham et al.32) RC US Nov 2010 to Sep 2013 219,027 GI bleeding D, R, or W
Maura et al.33) RC France Jul to Nov 2012 32,807 Effectiveness and bleeding D, R, or W
Graham et al.17) RC US Nov 2011 to Jun 2014 118,891 Stroke, bleeding, and mortality R vs. D
Noseworthy et al.11) RC US Oct 2010 to Feb 2015 31,574 Effectiveness and bleeding D, R, or W
Deitelzweig et al.34) RC US Jan 2012 to Mar 2014 74,730 Bleeding-related hospital readmissions D, R, or W
Coleman et al.35) RC US Jan 2012 to Oct 2014 38,831 Stroke, ICH A, R, or W
Lip et al.36) RC US Jan 2012 to Dec 2013 29,338 Bleeding A, D, R, or W
Halvorsen et al.37) Registry Norway Jan 2013 to Jun 2015 32,675 Bleeding A, D, R, or W
Chan et al.15) RC Taiwan Feb 2013 to Dec 2013 304,252 Effectiveness and bleeding D, R, or W
Larsen et al.12) RC Denmark Aug 2011 to Oct 2015 61,678 Effectiveness and bleeding A, D, R, or W
Yao et al.38) RC US Oct 2010 to Jun 2015 125,243 Effectiveness and bleeding A, D, R, or W
Lip et al.39) RC US Jan 2012 to Dec 2014 33,262 Major bleeding A, D, R, or W
Gorst-Rasmussen et al.16) Registry Denmark Feb 2012 to Jul 2014 22,358 Effectiveness and bleeding D, R, or W
Staerk et al.13) Registry Denmark Aug 2011 to Dec 2015 54,312 Effectiveness and ICH A, D, R, or W
Lamberts et al.22) Registry Denmark Aug 2011 to Dec 2015 54,312 Bleeding and non-persistence A, D, R, or W
Hohnloser et al.40) Registry Germany Jan 2013 to Mar 2015 35,013 Bleeding A, D, R, or W
Hernandez and Zhang18) RC US Nov 2011 to Dec 2013 17,507 Effectiveness and bleeding R vs. D
A = apixaban; D = dabigatran; GI = gastrointestinal; ICH = intracranial hemorrhage; NOAC = non-vitamin K antagonist oral anticoagulant; R = rivaroxaban; RC = 
retrospective cohort; W = warfarin.
apixaban was not associated with a significantly lower risk of stroke/TE than in patients 
administered anticoagulants (Figure 1).
In a recent systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, 
but was more effective than warfarin for the prevention of stroke/TE in patients with AF.14) 
Rivaroxaban was associated with a similar risk of stroke/TE to dabigatran11)15-18) (hazard ratio 
[HR], 1.02; 95% confidence interval [CI], 0.91–1.13; I2=70.2%, n=5), with a pooled rate 
for rivaroxaban at 0.3%/year vs. dabigatran at 0.3%/year (Figure 2).14) Noseworthy et al.11) 
835https://e-kcj.org https://doi.org/10.4070/kcj.2017.0158
NOAC Real-world Data and Doses for Koreans
A. Rivaroxaban vs. warfarin
HR (95% CI)Study (outcome)
Favor rivaroxaban Favor warfarin1 20
0.71 (0.47–1.07)
0.91 (0.74–1.12)
0.72 (0.51–1.01)
0.46 (0.26–0.82)
0.77 (0.55–1.09)
0.93 (0.72–1.19)
0.83 (0.69–0.99)
0.51 (0.35–0.74)
0.93 (0.47–1.85)
Gorst-Rasmussen et al.16)
Coleman et al.35) (IS)
Staerk et al.13)
High-dose
Low-dose
Laliberté et al.30)
Yao et al.38)
Larsen et al.12)
Chan et al.15)
Maura et al.33)
Bouillon et al.31) 0.75 (0.39–1.45)
B. Dabigatran vs. warfarin
HR (95% CI)Study (outcome)
Favor dabigatran Favor warfarin1 20
Staerk et al.13) 1.11 (0.84–1.42)
Yao et al.38) 0.98 (0.76–1.26)
Larsen et al.12) 1.17 (0.89–1.54)
Chan et al.15) 0.64 (0.49–0.83)
C. Apixaban vs. warfarin
HR (95% CI)Study (outcome)
Favor apixaban Favor warfarin
1 320
Staerk et al.13) 1.45 (0.99–1.93)
Yao et al.38) 0.67 (0.46–0.98)
Larsen et al.12) 1.08 (0.91–1.27)
Chan et al.15) 1.13 (0.49–2.63)
Figure 1. Comparison of each NOAC and warfarin in risk of stroke/TE in patients with AF. 
AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio; NOAC = non-vitamin K antagonist oral anticoagulant; TE = thromboembolism.
HR (95% CI)Study (outcome)
Favor rivaroxaban Favor warfarin1 20
High-dose
0.97 (0.66–1.42)Gorst-Rasmussen et al.16)
1.05 (0.97–1.13)Hernandez and Zhang18) (IS)
0.81 (0.65–1.01)Graham et al.17) (IS)
1.28 (1.14–1.44)Hernandez and Zhang18) (TE)
Low-dose
0.76 (0.47–1.23)Gorst-Rasmussen et al.16)
1.05 (0.94–1.18)Hernandez and Zhang18) (IS)
0.88 (0.65–1.20)Graham et al.17)  (IS)
1.37 (1.15–1.62)Hernandez and Zhang18) (TE)
0.78 (0.54–1.13)
Both-dose
1.00 (0.75–1.32)Norseworthy et al.11)
Chan et al.15) (IS/TE)
Figure 2. Rivaroxaban compared with dabigatran in risk of stroke/TE in patients with AF. 
AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio; IS = ischemic stroke; TE = thromboembolism.
reported that apixaban was as effective as rivaroxaban and dabigatran in the prevention of 
stroke/systemic embolism in patients with AF.
REAL-WORLD NOAC DATA: BLEEDING
Each NOAC compared with warfarin in risk of major bleeding in patients with AF
Figure 3 shows the comparison of each NOAC with warfarin in risk of major bleeding in 
patients with AF. In the real-world study with elderly Medicare users of dabigatran,19) at the 
150 mg twice-daily dose, the risk of intracranial bleeding and mortality in patients aged 
≥65 was significantly reduced compared with that of warfarin. Similar observations were 
shown in real-world studies with elderly patients from other countries such as Canada.20) 
Carmo et al.21) published a meta-analysis of several observational trials of dabigatran. In 
total, 210,279 and 510,019 patients treated with dabigatran and warfarin, respectively, were 
included in the meta-analysis, which showed significant difference in mortality, intracranial 
hemorrhage, and major bleeding, in favor of dabigatran. Subgroup analysis showed greater 
benefits in the prevention of ischemic stroke with dabigatran than with warfarin in the 
elderly, but there was no significant benefit over warfarin for major bleeding related to age. 
The increased evidence of gastrointestinal bleeding with dabigatran 150 mg twice daily 
was in line with the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-
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A. Dabigatran vs. warfarin
HR (95% CI)Study (outcome)
Favor dabigatran Favor warfarin1 20
0.66 (0.53–0.79)
0.69 (0.50–0.96)
0.79 (0.67–0.94)
0.61 (0.51–0.74)
0.65 (0.48–0.88)
0.74 (0.66–0.84)
0.88 (0.64–1.21)
0.79 (0.61–1.03)
0.88 (0.64–1.21)
Larsen et al.12) (AB)
Staerk et al.13)
Lip et al.36)
Yao et al.38)
Chan et al.15)
Halvorsen et al.37)
Maura et al.33)
Abraham et al.32) (GI)
Lip et al.36)
Bouillon et al.31) 0.78 (0.54–1.09)
0.68 (0.51–0.90)
0.80 (0.62–0.99)
0.53 (0.39–0.71)
0.45 (0.34–0.59)
0.63 (0.53–0.76)
0.70 (0.61–0.80)
0.52 (0.30–0.89)
Staerk et al.13) (ICH)
Hohnloser et al.40)
Lip et al.36)
Yao et al.38)
Larsen et al.12) (AB)
Halvorsen et al.37)
Lip et al.36)
Coleman et al.35) (ICH) 0.38 (0.17–0.88)
B. Apixaban vs. warfarin
HR (95% CI)Study (outcome)
Favor apixaban Favor warfarin1 20
Staerk et al.13) (ICH)
Lip et al.36)
Laliberté et al.30)
Yao et al.38)
Larsen et al.12)
Chan et al.15)
Halvorsen et al.37)
0.87 (0.67–1.08)
0.98 (0.83–1.17)
1.08 (0.71–1.64)
1.04 (0.90–1.20)
1.06 (0.91–1.23)
0.77 (0.53–1.13)
0.86 (0.68–1.10)
C. Rivaroxaban vs. warfarin
HR (95% CI)Study (outcome)
Favor rivaroxaban Favor warfarin1 20
Figure 3. Comparison of each NOAC and warfarin in risk of major bleeding in patients with AF. 
AB = any bleeding; AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio; ICH = intracranial hemorrhage; NOAC = non-vitamin K antagonist oral 
anticoagulant.
LY) trial, whereas dabigatran 110 mg twice daily showed no difference in gastrointestinal 
bleeding from warfarin.
In Danish nationwide registries, both apixaban and dabigatran had significantly lower risks 
of death, any bleeding, or major bleeding than did warfarin.12)13) In patients with high stroke 
and bleeding risks, dabigatran was the only NOAC associated with persistence of a significant 
low risk of intracranial bleeding. Another study showed that apixaban had a lower adjusted 
major bleeding risk than those of rivaroxaban, dabigatran, and warfarin.22)
However, rivaroxaban was comparable to warfarin in major bleeding incidences, with an 
increased risk of gastrointestinal bleeding and decreased risk of intracranial hemorrhage.14)
Comparison of NOACs in risk of major bleeding in patients with AF
Figure 4 shows the comparison of NOACs in risk of major bleeding in patients with AF. In a 
recent systematic review and meta-analysis, the major bleeding risk was significantly higher 
with rivaroxaban than it was with dabigatran (Figure 4A) or apixaban (Figure 4B), as were 
all-cause mortality and gastrointestinal bleeding. Rivaroxaban was associated with increased 
risk of all-cause mortality15-18) (HR, 1.23; 95% CI, 1.12–1.33), any bleeding 16-18) (HR, 1.33; 95% 
CI, 1.17–1.49), and gastrointestinal bleeding15)17)18) (HR, 1.33; 95% CI, 1.18–1.48), but with 
similar risk of acute myocardial infarction15)17) (HR, 0.81; 95% CI, 0.43–1.19) and intracranial 
hemorrhage11)15)17)18) (HR, 1.22; 95% CI, 0.85–1.59) compared with dabigatran. Apixaban was 
comparable to dabigatran in major bleeding (Figure 4C).
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A. Rivaroxaban vs. dabigatran
HR (95% CI)Study (outcome)
Favor rivaroxaban Favor dabigatran1 20
1.58 (1.32–1.50)
1.51 (1.25–1.85)
1.48 (1.32–1.67)
1.32 (1.17–1.50)
1.38 (1.27–1.49)
1.05 (0.74–1.49)
1.26 (0.87–1.85)
Graham et al.17) (ECH)
Hernandez and Zhang18)
Hernandez and Zhang18)
Hernandez and Zhang18)
Lip et al.39)
Chan et al.15)
Noseworthy et al.11)
High-dose
Low-dose
Both-dose Lip et al.39)
Noseworthy et al.11)
Lambert et al.22)
Deitelzweig et al.34)
-Bleeding admission
-All admission
Favor rivaroxaban Favor apixaban
B. Rivaroxaban vs. apixaban
Study (outcome)
1 2 3 40
HR (95% CI)
1.20 (1.1–1.3)
1.49 (1.27–1.77)
2.56 (1.85–3.57)
1.82 (1.36–2.43)
1.40 (1.1–1.8)
Noseworthy et al.11)
Lambert et al.22)
Deitelzweig et al.34)
-Bleeding admission
-All admission
C. Dabigatran vs. apixaban
HR (95% CI)Study (outcome)
Favor dabigatran Favor apixaban
1 320
2.0 (1.42–2.80)
1.10 (1.0–1.2)
1.20 (0.9–1.6)
1.17 (1.0–1.38)
Figure 4. Comparison of NOACs in risk of major bleeding in patients with AF. 
AF = atrial fibrillation; CI = confidence interval; ECH = extracranial hemorrhage; HR = hazard ratio; NOAC = non-vitamin K antagonist oral anticoagulant.
REAL-WORLD DATA FOR THE REDUCED DOSAGE OF NOAC
While NOACs do not require the meticulous dose adjustments required for warfarin, a 
clinical evaluation of appropriate (constant) doses is still necessary. A significant minority 
(approximately 1 in 8) of US patients in the community received NOAC doses inconsistent 
with labeling. NOAC over- and under-dosing are associated with an increased risk for adverse 
events.23) The efficacy and safety of reduced NOAC doses were reported in several studies. 
Recently, Nielsen et al.24) reported that, in the propensity weighted Danish nationwide 
study of reduced-dose NOAC regimens, apixaban 2.5 mg twice a day was associated with an 
increasing trend of ischemic stroke/systemic embolism rates compared with warfarin, while 
rivaroxaban 15 mg once a day and dabigatran 110 mg twice a day showed a trend of lower 
thromboembolic rates. The results were not significantly different. Rates of bleeding (the 
principal safety outcome) were significantly lower for dabigatran than for other agents, but 
did not significantly differ for apixaban and rivaroxaban compared with warfarin. Because 
the efficacy and safety were changed by reducing the dosage of NOAC, strict adherence to the 
dose reduction guideline is necessary.
Varying degrees of renal function require recommendations for reduced dosing regimens 
of these drugs; however, different cut-off values for age, body weight, or interacting drugs 
also require consideration for appropriate dose selection.25) Indeed, both age and chronic 
kidney disease in patients with AF intensify the risk of stroke and increase the risk of bleeding 
during antithrombotic treatment.26) In routine clinical practice, prescribed NOAC doses are 
often inconsistent with drug labeling. These prescribing patterns might be associated with 
worse safety profiles with no benefit in effectiveness in patients with severe kidney disease 
and worse effectiveness with no benefit in safety in apixaban-treated patients with normal or 
mildly impaired renal function.27)
RECOMMENDATION OF DOSE REGIMEN FOR KOREAN 
PATIENTS
Elderly patients with AF (such as those aged ≥80 years) and patients with impaired renal 
function were included in the landmark trials of NOACs, but these important subgroups 
comprised only a small proportion of the patient populations. For dabigatran, reduction of 
the daily recommended dose to 110 mg twice daily is indicated for patients aged ≥80 years. 
This dose can be reduced to 110 mg twice daily if the patient is aged 75–79 years and has other 
comorbidities that could affect bleeding risk such as previous gastritis, peptic ulcer disease, 
and moderate renal impairment. Indeed, label (or guideline) adherent use of dabigatran 
is clearly associated with better outcomes for stroke, major bleeding, and mortality.28)29) 
Insufficient published data for apixaban, edoxaban, and rivaroxaban indicate that further 
work is needed to clarify the bleeding risks of these NOACs in the elderly.
For Korean patients with AF, a reduced dosing regimen for dabigatran (110 mg twice a day) in 
patients aged ≥80 years or who have an estimated glomerular filtration rate (eGFR) of 30–50 
mL/min; rivaroxaban (15 mg once daily) in patients aged ≥80 years or with an eGFR of 15–49 
mL/min; apixaban (2.5 mg twice a day) if 2 of the 3 following criteria are present: age ≥80 
years or an eGFR 15–29 mL/min or body weight ≤60 kg; or edoxaban (30 mg once daily) if 
eGFR is 15–50 mL/min are recommended (Table 2).
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CONCLUSION
Real-world data is complementary to large randomized phase III trials by providing new 
information on the real-world absolute risks of ischemic and hemorrhagic stroke with NOACs 
vs. VKA. This paper highlighted recently published real-world data of NOACs and further 
recommended dosages for NOACs for Korean patients.
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